Mathematic models for cancer chemotherapy: pharmacokinetic and cell kinetic considerations.

Cancer chemotherapy reports Pub Date : 1975-07-01
S Chuang
{"title":"Mathematic models for cancer chemotherapy: pharmacokinetic and cell kinetic considerations.","authors":"S Chuang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>This paper presents a theoretic study of pharmacokinetic and cell kinetic models for cancer chemotherapeutic systems. The mathematic analysis is based on a modified procedure deduced from DeVita's scheme of the relationship between the cellular kinetics of normal and tumor tissues and the pharmacokinetics of antitumor agents for designing an optimal dose and schedule for cancer treatment. In this scheme pharmacokinetic models and cell-drug interactions at the tumor site are incorporated into the cell cycle kinetic models to form the cancer chemotherapeutic model systems. Three cell cycle kinetic models are presented under alternative hypotheses concerning the mechanism of the resting cells, while each tumor mass is comprised of cells in proliferating (consisting of the four cycle phases G1, S, G2, and M), resting (Go), and non dividing (D, dead) states. An algorithm and a computer program for simulating the tumor populations during scheduled treatments have been prepared. By a suitable selection of expressions for cell-drug interactions, the program is able to simulate tumor behavior during scheduled treatments with different classes of anticancer agent such as cell cycle phase-specific, cell cycle-specific, or cell cycle-specific, or cell cycle-nonspecific drugs. A preliminary study of the L1210-ara-C therapeutic system is included to demonstrate the computer simulation procedures.</p>","PeriodicalId":9510,"journal":{"name":"Cancer chemotherapy reports","volume":"59 4","pages":"827-42"},"PeriodicalIF":0.0000,"publicationDate":"1975-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer chemotherapy reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

This paper presents a theoretic study of pharmacokinetic and cell kinetic models for cancer chemotherapeutic systems. The mathematic analysis is based on a modified procedure deduced from DeVita's scheme of the relationship between the cellular kinetics of normal and tumor tissues and the pharmacokinetics of antitumor agents for designing an optimal dose and schedule for cancer treatment. In this scheme pharmacokinetic models and cell-drug interactions at the tumor site are incorporated into the cell cycle kinetic models to form the cancer chemotherapeutic model systems. Three cell cycle kinetic models are presented under alternative hypotheses concerning the mechanism of the resting cells, while each tumor mass is comprised of cells in proliferating (consisting of the four cycle phases G1, S, G2, and M), resting (Go), and non dividing (D, dead) states. An algorithm and a computer program for simulating the tumor populations during scheduled treatments have been prepared. By a suitable selection of expressions for cell-drug interactions, the program is able to simulate tumor behavior during scheduled treatments with different classes of anticancer agent such as cell cycle phase-specific, cell cycle-specific, or cell cycle-specific, or cell cycle-nonspecific drugs. A preliminary study of the L1210-ara-C therapeutic system is included to demonstrate the computer simulation procedures.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
癌症化疗的数学模型:药代动力学和细胞动力学考虑。
本文对肿瘤化疗系统的药代动力学和细胞动力学模型进行了理论研究。数学分析是根据DeVita的正常组织和肿瘤组织的细胞动力学与抗肿瘤药物的药代动力学之间的关系的方案推导出的改进程序,以设计最佳的剂量和治疗方案。在该方案中,药物动力学模型和肿瘤部位的细胞-药物相互作用被纳入细胞周期动力学模型,形成癌症化疗模型系统。在关于静止细胞机制的不同假设下,提出了三种细胞周期动力学模型,而每个肿瘤块由增殖(由G1、S、G2和M四个周期阶段组成)、静止(Go)和非分裂(D,死亡)状态的细胞组成。已经编制了一种算法和计算机程序,用于模拟预定治疗期间的肿瘤种群。通过适当选择细胞-药物相互作用的表达,该程序能够在使用不同类型的抗癌药物(如细胞周期阶段特异性、细胞周期特异性、细胞周期特异性或细胞周期非特异性药物)进行预定治疗期间模拟肿瘤行为。对L1210-ara-C治疗系统进行了初步研究,以演示计算机模拟程序。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
PORFIROMYCIN. Phase I study of 5-azacytidine (NSC-102816) using 24-hour continuous infusion for 5 days. Bleomycin (NSC-125066) and CCNU (NSC-79037) in the combination chemotherapy of mopp-resistant hodgkin's disease. Combination chemotherapy with 5-fluorouracil (NSC-19893), methotrexate (NSC-740), and prednisolone (NSC-9900) (FAP protocol) for hepatoma. Cyclophosphamide (NSC-26271) maintenance therapy after a second remission of childhood acute lymphoblastic leukemia: comparative clinical trial (standard dose versus intermittent high dose versus cyclophosphamide plus cytosine arabinoside (NSC-63878)).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1